Payment overview · 2025
General Payments
$2,140.13
98 reported records · 27 companies
Healthcare provider profile · identity verified
Bahige Asaker, DO
Allopathic & Osteopathic Physicians|Internal Medicine · BROCKTON, MA · NPI 1104927102
Verified facts
What the public records show
CMS Open Payments records show Bahige Asaker, DO received $2,140.13 in general payments during 2025 across 98 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 346 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 346 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1059 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $395.98 | 18.5% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $251.28 | 11.7% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $203.25 | 9.5% | 13 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $102.89 | 4.8% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $102.50 | 4.8% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $101.79 | 4.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $101.15 | 4.7% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.59 | 3.7% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $79.03 | 3.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.68 | 2.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.49 | 2.9% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $56.82 | 2.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.15 | 2.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $50.10 | 2.3% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$49.31 | 2.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $47.20 | 2.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $46.61 | 2.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.42 | 2.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.95 | 2.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.95 | 1.9% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $34.51 | 1.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.08 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.14 | 1.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $23.19 | 1.1% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.90 | 1.0% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $18.85 | 0.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.32 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,140.13 | 98 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $274.24 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $204.68 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $117.81 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $102.50 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.84 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $79.59 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $79.03 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $78.37 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.20 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $70.62 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.59 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.49 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $62.49 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $56.82 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $56.82 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $54.65 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $54.65 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $54.65 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $53.73 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $50.15 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $50.15 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $50.10 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.42 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $47.20 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $46.61 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.42 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $43.37 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.95 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.95 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $25.72 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $21.90 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1059 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 94 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 346 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
94 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
346 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
346 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
98 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1059 | 89 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2237 | 307 |
| Trazodone Hcl | Trazodone Hcl | 2046 | 124 |
| Furosemide | Furosemide | 1326 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 1121 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1070 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 1060 | 147 |
| Eliquis | Apixaban | 1059 | 89 |
| Gabapentin | Gabapentin | 1028 | 116 |
| Mirtazapine | Mirtazapine | 1025 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 769 | 152 |
| Divalproex Sodium | Divalproex Sodium | 742 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 716 | 96 |
| Lisinopril | Lisinopril | 672 | 107 |
| Metformin Hcl | Metformin Hcl | 580 | 110 |
| Escitalopram Oxalate | Escitalopram Oxalate | 565 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 532 | 61 |
| Olanzapine | Olanzapine | 516 | 36 |
| Losartan Potassium | Losartan Potassium | 454 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 452 | 33 |
| Omeprazole | Omeprazole | 442 | 90 |
| Simvastatin | Simvastatin | 409 | 53 |
| Potassium Chloride | Potassium Chloride | 397 | 36 |
| Sertraline Hcl | Sertraline Hcl | 373 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 363 | 43 |
| Jardiance | Empagliflozin | 346 | 48 |
| Januvia | Sitagliptin Phosphate | 315 | 34 |
| Baclofen | Baclofen | 311 | 21 |
| Risperidone | Risperidone | 284 | 18 |
| Levetiracetam | Levetiracetam | 268 | 28 |
| Famotidine | Famotidine | 253 | 30 |
| Buspirone Hcl | Buspirone Hcl | 251 | 15 |
| Tramadol Hcl | Tramadol Hcl | 251 | 64 |
| Ibuprofen | Ibuprofen | 249 | 68 |
| Citalopram Hbr | Citalopram Hydrobromide | 246 | 29 |
| Xarelto | Rivaroxaban | 242 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 228 | 65 |
| Prednisone | Prednisone | 228 | 127 |
| Glipizide | Glipizide | 220 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 216 | 26 |
| Lorazepam | Lorazepam | 209 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 192 | 22 |
| Benztropine Mesylate | Benztropine Mesylate | 191 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 183 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 172 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 26 |
| Finasteride | Finasteride | 161 | 43 |
| Atenolol | Atenolol | 155 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 29 |
| Memantine Hcl | Memantine Hcl | 152 | 24 |
| Montelukast Sodium | Montelukast Sodium | 144 | 20 |
| Ozempic | Semaglutide | 144 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 44 |
| Nifedipine Er | Nifedipine | 141 | 17 |
| Midodrine Hcl | Midodrine Hcl | 136 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 133 | 34 |
| Lamotrigine | Lamotrigine | 133 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 124 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 122 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 122 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | suppressed |
| Allopurinol | Allopurinol | 115 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 111 | 35 |
| Azithromycin | Azithromycin | 110 | 77 |
| Sucralfate | Sucralfate | 108 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 105 | suppressed |
| Clonazepam | Clonazepam | 103 | 20 |
| Fluphenazine Hcl | Fluphenazine Hcl | 102 | suppressed |
| Trulicity | Dulaglutide | 98 | 16 |
| Alprazolam | Alprazolam | 94 | 22 |
| Farxiga | Dapagliflozin Propanediol | 94 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 92 | 18 |
| Warfarin Sodium | Warfarin Sodium | 89 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 32 |
| Spironolactone | Spironolactone | 87 | 17 |
| Venlafaxine Hcl | Venlafaxine Hcl | 86 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 79 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 77 | suppressed |
| Glimepiride | Glimepiride | 77 | 24 |
| Aripiprazole | Aripiprazole | 75 | suppressed |
| Lactulose | Lactulose | 75 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 71 | 11 |
| Haloperidol | Haloperidol | 71 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 69 | 12 |
| Carvedilol | Carvedilol | 68 | 16 |
| Primidone | Primidone | 68 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 64 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 64 | 30 |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | suppressed |
| Amoxicillin | Amoxicillin | 61 | 46 |
| Torsemide | Torsemide | 61 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 15 |
| Myrbetriq | Mirabegron | 59 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 15 |
| Celecoxib | Celecoxib | 57 | suppressed |
| Entresto | Sacubitril/Valsartan | 57 | suppressed |
| Creon | Lipase/Protease/Amylase | 56 | suppressed |
| Cephalexin | Cephalexin | 55 | 41 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | suppressed |
| Humalog | Insulin Lispro | 54 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 54 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 53 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 53 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 53 | suppressed |
| Ranolazine Er | Ranolazine | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | suppressed |
| Latanoprost | Latanoprost | 49 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 15 |
| Ezetimibe | Ezetimibe | 48 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 48 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 46 | 12 |
| Lidocaine | Lidocaine | 46 | 13 |
| Naproxen | Naproxen | 44 | 19 |
| Valproic Acid | Valproic Acid | 43 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 41 | suppressed |
| Nystatin | Nystatin | 41 | 21 |
| Cabergoline | Cabergoline | 40 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 40 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 26 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 33 | 24 |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | 13 |
| Ondansetron Odt | Ondansetron | 33 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | 15 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 14 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 31 | 17 |
| Klor-Con M20 | Potassium Chloride | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 31 | 14 |
| Brilinta | Ticagrelor | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 22 |
| Valsartan | Valsartan | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 16 |
| Clozapine | Clozapine | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | 11 |
| Heparin Sodium | Heparin Sodium,porcine | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 16 |
| Dovato | Dolutegravir Sodium/Lamivudine | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 26 | 11 |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 25 | 19 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 22 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 22 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 22 | suppressed |
| Roflumilast | Roflumilast | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Nyamyc | Nystatin | 19 | 11 |
| Ramelteon | Ramelteon | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 17 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 15 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Pulmicort Flexhaler | Budesonide | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Levocarnitine | Levocarnitine | 13 | suppressed |
| Rhopressa | Netarsudil Mesylate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Perphenazine | Perphenazine | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Yupelri | Revefenacin | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,140.13 · 98 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, INGREZZA, INTELLIS ADAPTIVESTIM, JARDIANCE, JASCAYD, LEQVIO, Leqembi, MINIMED 780G, MOUNJARO, NURTEC ODT, ONPATTRO, Ohtuvayre, PAXLOVID, PREVNAR 20, REXULTI, SHINGRIX, The Cologuard Plus Collection Kit, UNITHROID, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error